Loading clinical trials...
Loading clinical trials...
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monothe...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
Collaborators
NCT06961357 · Melanoma
NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT07436078 · Female Breast Cancer, Prostate Cancer, and more
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
UCLA Medical Hematology & Oncology
Los Angeles, California
UCSF
San Francisco, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions